CryoLife, Inc. (NYSE:CRY) Releases FY17 Earnings Guidance

CryoLife, Inc. (NYSE:CRY) issued an update on its FY17 earnings guidance on Monday morning. The company provided earnings per share guidance of $0.40-0.43 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.41. The company issued revenue guidance of $184-185 million, compared to the consensus revenue estimate of $187.96 million.

CryoLife, Inc. (CRY) traded up $0.30 during trading on Wednesday, hitting $19.35. The company had a trading volume of 168,900 shares, compared to its average volume of 164,557. The stock has a market capitalization of $637.37, a PE ratio of 46.46 and a beta of 0.82. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.96 and a quick ratio of 4.90. CryoLife, Inc. has a 12 month low of $14.02 and a 12 month high of $24.00.

CryoLife (NYSE:CRY) last posted its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.08. The firm had revenue of $44.00 million for the quarter, compared to analysts’ expectations of $44.60 million. CryoLife had a return on equity of 6.43% and a net margin of 5.28%. The business’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.13 EPS. research analysts anticipate that CryoLife, Inc. will post 0.28 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on the company. BidaskClub cut CryoLife from a buy rating to a hold rating in a report on Monday, July 24th. Zacks Investment Research upgraded CryoLife from a sell rating to a hold rating in a report on Monday, August 14th. Lake Street Capital boosted their price objective on CryoLife to $26.00 and gave the company a buy rating in a report on Wednesday, October 11th. Northland Securities reiterated a buy rating and issued a $23.50 target price on shares of CryoLife in a report on Monday. Finally, TheStreet lowered CryoLife from a b rating to a c+ rating in a research report on Monday, October 30th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $23.63.

In other news, CAO Amy Horton sold 4,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total value of $76,000.00. Following the sale, the chief accounting officer now owns 98,705 shares in the company, valued at $1,875,395. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James P. Mackin sold 125,000 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total value of $2,751,250.00. Following the transaction, the chief executive officer now owns 398,399 shares in the company, valued at approximately $8,768,761.99. The disclosure for this sale can be found here. Insiders sold 209,240 shares of company stock worth $4,495,465 over the last three months. Corporate insiders own 6.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “CryoLife, Inc. (NYSE:CRY) Releases FY17 Earnings Guidance” was posted by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Earnings History and Estimates for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with's FREE daily email newsletter.

Leave a Reply